Using Blood Tests to Predict Thrombosis Risk and Outcomes in Patients Undergoing Surgical or Transcatheter Aortic Valve Replacement

What this Trial Is About

Researchers are studying patients with aortic valve disease who are undergoing either surgical aortic valve replacement SAVR or transcatheter aortic valve implantation TAVI to understand the risk of thrombosis and related complications. This observational study aims to use novel blood biomarkers to assess clotting and clot breakdown, identifying patients at risk for valve thrombosis and related adverse events such as stroke, systemic embolism, and valve failure. The study also seeks to determine the time periods when the risk of valve thrombosis is highest. Participants will have blood tests at several time points to measure thrombosis and thrombolysis markers, which may be influenced by their prescribed blood-thinning medications. They will be monitored using 4D CT scans, echocardiography, and clinical reviews to detect adverse events including major cardiac and cerebrovascular events, valve thrombosis, bleeding, and new or worsening atrial fibrillation. These evaluations will continue regularly over a five-year follow-up period. Throughout the study, participants will provide blood samples and undergo imaging and clinical assessments to track their health and valve function. Researchers will closely observe clinical outcomes such as major cardiac events, strokes, systemic embolism, and bleeding over the five years. This long-term monitoring helps identify when patients face the greatest risks and how well blood tests predict these complications, supporting safer, targeted treatment approaches.

Avr Thrombosis OutcoMe Study